Tvardi Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Tvardi Therapeutics

10/05/2025 01:15

Tvardi Therapeutics Inc TVRD.OQ TVRD.O is expected to show a fall in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Tvardi Therapeutics Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​

Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $39.00​, above​ its last closing price of $25.61. ​​​

This summary was machine generated May 10 at 00:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)